Biotech

All Articles

Actinogen's cortisol blocker falls short stage 2 anxiety study

.Actinogen Medical's cortisol blocker has skipped the primary endpoint of a stage 2 research in clin...

Bivictrix decides going personal only method to take ADC in to medical clinic

.Antibody-drug conjugates (ADCs) have been at the center of several a billion-dollar biobuck licensi...

TPG tops up funds to $580M for assets all over life scientific researches

.Asset supervisor TPG, which has actually sustained biotechs like Sionna Therapies as well as Santa ...

Merck stops stage 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has gone through one more obstacle. Months after shuttering a stage 3 m...

After a challenging year, Exscientia folds right into Recursion

.After a year defined through pipeline cuts, the departure of its own CEO as well as layoffs, Exscie...

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Rehab was actually thrilled enough with Port BioMed's bispecific immune activator that it ...

A closer take a look at Tough Biotech's Ferocious 15

.Within this full week's incident of "The Leading Line," our company are actually diving in to Inten...

Lilly faces phase 2 breakdown of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's celebration celebrating the approval...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of considerable management hirings, firings...

Lykos are going to ask FDA to reexamine its own choice complying with rejection of MDMA treatment for post-traumatic stress disorder

.Complying with an unsatisfactory revealing for Lykos Therapies' MDMA prospect for post-traumatic st...